Vericiguat for people with heart failure and chronic kidney disease on dialysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational, single-arm study enrolling about 118 adults with chronic kidney disease and heart failure with reduced ejection fraction, many of whom are on dialysis. Participants will receive vericiguat and be followed in a real-world setting to record clinical events, tolerability, and treatment-related outcomes. The study targets patients with eGFR <90 ml/min/1.73 m2, NYHA class II or higher, LVEF ≤50%, and adequate dialysis adequacy (Kt/V>1.2 or URR>70%). Because randomized dialysis-specific trials are limited, this study aims to gather pragmatic safety and effectiveness data in this special population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient is aged between 18 and 80 years
* Suffering from chronic kidney disease (eGFR\<90ml/min/1.73m², by CKD-EPI formula).
* They have chronic heart failure (NYHA class ≥II), with reduced ejection fraction, defined as LVEF≤50%.
* Their serum potassium level has been ≤4.8 mmol/L in the past month.
* For women of childbearing potential, the pregnancy test result is negative at the screening visit and they agree.
* Adequate contraceptive measures are taken.
* The patient's dialysis adequacy assessment has reached Kt/V \>1.2, or URR\>70%.
* The study protocol is implemented after being approved by the hospital ethics committee, and all patients voluntarily participate in this study

Exclusion Criteria:

* Acute renal failure.
* Systolic blood pressure below 90 mmHg at screening (systolic blood pressure less than 95 mmHg during interdialytic period).
* Isolated right heart failure due to pulmonary disease; the primary cause of dyspnea is due to non-cardiac, non-heart failure reasons, such as acute or chronic respiratory diseases.
* History of myocardial infarction or cerebrovascular event within the past 3 months.
* History of angioedema.
* Hemodialysis patients with dialysis frequency less than 3 times per week.
* Significant laboratory abnormalities at screening that interfere with the assessment of the safety or efficacy of the study drug (e.g., serum potassium \> 5.5 mmol/L or \< 3.5 mmol/L, serum sodium \< 130 mmol/L, or alanine aminotransferase or aspartate aminotransferase \> 2 times the upper limit of the normal range).
* History of kidney transplantation or planned kidney transplantation within the next 12 months.
* Use of medications for pulmonary arterial hypertension, such as sildenafil, during the study period.
* Known allergy to the study treatment (active substance or excipients).
* Any other disease or treatment that makes the patient ineligible to participate in this study or to complete the entire planned study period (e.g., active malignancy or other diseases that limit life expectancy to less than 12 months).
* Pregnant or breastfeeding during the study period, or intending to become pregnant.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Shuangxin Liu — Guangdong Provincial People's Hospital
• Study coordinator: Shuangxin Liu
• Email: gdphgcp@gdph.org.an
• Phone: (+86)020-83525210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS

  Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07912086

• Tailored digital support to cut sedentary time in long-term cardiac rehab

  In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.

  Recruiting University of Lisbon · Lisbon, Lisbon District · NCT07910812

• NT-proBNP–guided heart failure screening for people 65+ in rural China

  This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.

  Recruiting Jiangsu Taizhou People's Hospital · Nanjing · NCT07885488

• Voice-based detection of heart failure deterioration using Noah Labs Vox

  This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.

  Recruiting Noah Labs · Boston, Massachusetts · NCT07870395

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.